0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessThe advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma.
Lavinia Tan, Shahneen Sandhu, Rebecca Lee, James Li, Jason Callahan, Sarah Ftouni, Nathalie Dhomen, Philippa Middlehurst, Andrea Wallace, Jeanette Raleigh, Athena Hatzimihalis, Michael A. Henderson, Mark Shackleton, Andrew Haydon, Victoria Mar, David Gyorki, D. Oudit, Mark A. Dawson, Rodney J. Hicks, Paul Lorigan, Grant A. McArthur, Richard Marais, Stephen Q. Wong, Sarah‐Jane Dawson (2019). Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. , 30(5), DOI: https://doi.org/10.1093/annonc/mdz048.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2019
Authors
24
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1093/annonc/mdz048
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
